Second-line Afatinib vs Erlotinib for Advanced Lung Squamous Cell Carcinoma: Final Analysis of the Phase 3 LUX-Lung 8 Trial

Goss, G. D.Cobo, M.Lu, S.Syrigos, K.Lee, K. H.Goker, E.Felip, E.2020-12-012020-12-0120191556-08641556-1380https://doi.org/10.1016/j.jtho.2019.09.165https://hdl.handle.net/11454/63277[No abstract available]en10.1016/j.jtho.2019.09.165info:eu-repo/semantics/openAccesslung SCCafatiniberlotinibsecond-lineSecond-line Afatinib vs Erlotinib for Advanced Lung Squamous Cell Carcinoma: Final Analysis of the Phase 3 LUX-Lung 8 TrialConference Object1411S1185S1185WOS:000494945000074Q1